Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1351 to 1365 of 1519 results for do not do recommendations

  1. Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)

    Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults.

  2. Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)

    NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19 .

  3. MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes (MIB51)

    NICE has developed a medtech innovation briefing (MIB) on MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes

  4. Idelalisib for treating refractory follicular lymphoma (TA604)

    Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.

  5. ORA G3 to measure corneal hysteresis (MIB150)

    NICE has developed a medtech innovation briefing (MIB) on ORA G3 to measure corneal hysteresis .

  6. Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (HTG360)

    Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the dose of 5-FU.

  7. Baricitinib for moderate to severe rheumatoid arthritis (TA466)

    Evidence-based recommendations on baricitinib (Olumiant) for moderate to severe rheumatoid arthritis in adults.

  8. Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)

    Evidence-based recommendations on abiraterone (Zytiga) for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in adults.

  9. Woundchek Protease Status for assessing elevated protease status in chronic wounds (MIB83)

    NICE has developed a medtech innovation briefing (MIB) on the Woundchek Protease Status for assessing elevated protease status in chronic wounds .

  10. Cannabidiol for treating seizures caused by tuberous sclerosis complex (TA873)

    Evidence-based recommendations on cannabidiol (Epidyolex) for treating seizures caused by tuberous sclerosis complex.

  11. Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable (TA917)

    Evidence-based recommendations on daratumumab (Darzalex) with lenalidomide and dexamethasone for untreated multiple myeloma in adults, when a stem cell transplant is unsuitable.

  12. Fasciotens for abdominal wall closure (MIB321)

    NICE has developed a medtech innovation briefing (MIB) on fasciotens for abdominal wall closure .

  13. ADXBLADDER for detecting bladder cancer (MIB180)

    NICE has developed a medtech innovation briefing (MIB) on ADXBLADDER for detecting bladder cancer .

  14. Ambu aScope 4 Broncho for routine diagnostic and therapeutic bronchoscopy (MIB314)

    NICE has developed a medtech innovation briefing (MIB) on Ambu aScope 4 Broncho for routine diagnostic and therapeutic bronchoscopy .

  15. Sacrocolpopexy with hysterectomy using mesh to repair uterine prolapse (IPG577)

    Evidence-based recommendations on sacrocolpopexy with hysterectomy using mesh to repair uterine prolapse. This involves attaching mesh from the top of the vagina to the base of the spine to support the pelvic organs after the womb has been removed.